For this second objective, the phase II SINDAS study was designed, which evaluated the addition of stereotactic body radiation therapy (SBRT) to first-generation TKIs in first-line therapy, demonstrating that the incorporation of upfront local therapy via radiotherapy, in contrast to the use of a first-line TKI alone, resulted in a statistically significant enhancement in PFS (20.2 months versus 12.5 months (p < 0.001) and OS (25.5 months versus 17.4 months (p < 0.001) for patients with EGFR-mutated NSCLC [59]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.